Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vaxart, Inc.VXRT · Entity 6654 | Chief Medical Officer | March 28, 2026 | March 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vaxart, Inc.
Report date March 28, 2026 · Filed March 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 924,177 |
Reported balance
After 2026-03-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-28 · Tax withholding · Disposed 3,292 · Balance 924,177 F1: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 28, 2026. F2: This amount includes 75,618 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 28, 2026.
F2: This amount includes 75,618 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 28, 2026 Filed Mar 31, 2026 20:44 UTC | Vaxart, Inc. VXRT · Entity 6654 | Tax withholdingCommon Stock | 3,292 | $0.65 | $2,139.80 |
DisclosureSEC source: 0001437749-26-010707 · rdgdoc.xml · nonDerivative · entry 1 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 924,177 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 28, 2026. F2 · balance_after: This amount includes 75,618 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. Read SEC document |
| March 24, 2026 Filed Mar 26, 2026 20:52 UTC | Vaxart, Inc. VXRT · Entity 6654 | Tax withholdingCommon Stock | 30,551 | $0.69 | $21,202.39 |
DisclosureSEC source: 0001437749-26-009968 · rdgdoc.xml · nonDerivative · entry 1 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 927,469 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 24, 2026. F2 · balance_after: This amount includes 75,618 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 19:15 UTC | Vaxart, Inc. VXRT · Entity 6654 | Tax withholdingCommon Stock | 6,772 | $0.63 | $4,297.51 |
DisclosureSEC source: 0001437749-26-009207 · rdgdoc.xml · nonDerivative · entry 1 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 958,020 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 18, 2026. F2 · balance_after: This amount includes 75,618 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 23:41 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 455,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001437749-26-008907 · rdgdoc.xml · derivative · entry 2 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 455,000 Underlying: Common Stock · 455,000 shares Expires 2036-03-16 F2 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 16, 2027, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 16, 2030. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 23:41 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 227,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-008907 · rdgdoc.xml · nonDerivative · entry 1 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 964,792 F1 · shares: Grant of shares upon vesting of restricted stock units. 25% of the shares underlying the award shall vest on each anniversary of the vesting commencement date of March 16, 2026, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 23:54 UTC | Vaxart, Inc. VXRT · Entity 6654 | Tax withholdingCommon Stock | 7,965 | $0.61 | $4,846.70 |
DisclosureSEC source: 0001437749-26-003255 · rdgdoc.xml · nonDerivative · entry 1 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 737,792 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of February 2, 2026. F2 · balance_after: This amount includes 75,618 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 22:46 UTC | Vaxart, Inc. VXRT · Entity 6654 | Tax withholdingCommon Stock | 3,292 | $0.42 | $1,386.59 |
DisclosureSEC source: 0001437749-25-010519 · rdgdoc.xml · nonDerivative · entry 1 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 745,757 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 28, 2025. Read SEC document |
| March 24, 2025 Filed Mar 27, 2025 01:52 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001437749-25-009448 · rdgdoc.xml · derivative · entry 3 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-03-24 F2 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 24, 2026, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 24, 2029. Read SEC document |
| March 24, 2025 Filed Mar 27, 2025 01:52 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 610,000 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001437749-25-009448 · rdgdoc.xml · derivative · entry 2 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 610,000 Underlying: Common Stock · 610,000 shares Expires 2035-03-24 F2 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 24, 2026, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 24, 2029. Read SEC document |
| March 24, 2025 Filed Mar 27, 2025 01:52 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 406,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-009448 · rdgdoc.xml · nonDerivative · entry 1 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 749,049 F1 · shares: Grant of shares upon vesting of restricted stock units. 25% of the shares underlying the award shall vest on each anniversary of the vesting commencement date of March 24, 2025, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date. Read SEC document |
| March 18, 2025 Filed Mar 21, 2025 01:43 UTC | Vaxart, Inc. VXRT · Entity 6654 | Tax withholdingCommon Stock | 6,772 | $0.57 | $3,861.39 |
DisclosureSEC source: 0001437749-25-008653 · rdgdoc.xml · nonDerivative · entry 2 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,049 F3 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 18, 2025. F4 · balance_after: Includes 75,618 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. Read SEC document |
| February 02, 2025 Filed Feb 5, 2025 01:11 UTC | Vaxart, Inc. VXRT · Entity 6654 | Tax withholdingCommon Stock | 7,964 | $0.68 | $5,413.93 |
DisclosureSEC source: 0001437749-25-002802 · rdgdoc.xml · nonDerivative · entry 1 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 318,837 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of February 2, 2025. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 23:13 UTC | Vaxart, Inc. VXRT · Entity 6654 | Tax withholdingCommon Stock | 3,292 | $1.30 | $4,279.60 |
DisclosureSEC source: 0001437749-24-010473 · rdgdoc.xml · nonDerivative · entry 1 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 326,801 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested on March 28, 2024. Read SEC document |
| March 18, 2024 Filed Mar 21, 2024 00:09 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 410,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001437749-24-008750 · rdgdoc.xml · derivative · entry 4 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 410,000 shares Expires 2034-03-17 F6 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 18, 2025, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 18, 2028. Read SEC document |
| March 18, 2024 Filed Mar 21, 2024 00:09 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-008750 · rdgdoc.xml · nonDerivative · entry 3 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,093 F5 · shares: Grant of shares upon vesting of restricted stock units. Twenty five percent of the shares underlying the award shall vest on each anniversary of the vesting commencement date of March 18, 2024, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date. Read SEC document |
| February 02, 2024 Filed Mar 21, 2024 00:09 UTC | Vaxart, Inc. VXRT · Entity 6654 | Tax withholdingCommon Stock | 7,965 | $1.20 | $9,558.00 |
DisclosureSEC source: 0001437749-24-008750 · rdgdoc.xml · nonDerivative · entry 2 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,093 F1 · date: This transaction is being reported late due to administrative oversight. F4 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of February 2, 2024. Read SEC document |
| December 08, 2023 Filed Mar 21, 2024 00:09 UTC | Vaxart, Inc. VXRT · Entity 6654 | Tax withholdingCommon Stock | 31,409 | $0.71 | $22,300.39 |
DisclosureSEC source: 0001437749-24-008750 · rdgdoc.xml · nonDerivative · entry 1 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 248,058 F1 · date: This transaction is being reported late due to administrative oversight. F2 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of December 8, 2023. F3 · balance_after: This amount includes 41,367 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. Read SEC document |
| March 28, 2023 Filed Mar 21, 2025 01:43 UTC | Vaxart, Inc. VXRT · Entity 6654 | Tax withholdingCommon Stock | 3,267 | $0.75 | $2,450.90 |
DisclosureSEC source: 0001437749-25-008653 · rdgdoc.xml · nonDerivative · entry 1 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 349,821 F1 · date: This transaction is being reported late due to administrative oversight. F2 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 28, 2023. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:53 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 410,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001437749-23-007439 · rdgdoc.xml · derivative · entry 5 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 410,000 shares Expires 2033-03-16 F4 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on February 2, 2024, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on February 2, 2027. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:53 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 205,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001437749-23-007439 · rdgdoc.xml · derivative · entry 4 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,000 Underlying: Common Stock · 205,000 shares Expires 2033-03-16 F2 · derivative.exercise_date: The shares subject to this stock option shall fully vest on December 8, 2023. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:53 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-007439 · rdgdoc.xml · nonDerivative · entry 3 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,100 F3 · shares: Grant of shares upon vesting of restricted stock units. Twenty five percent of the shares underlying the award shall vest on each anniversary of the vesting commencement date of February 2, 2023, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:53 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 59,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-007439 · rdgdoc.xml · nonDerivative · entry 2 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,100 F1 · shares: Grant of shares upon vesting of restricted stock units, which shall fully vest on December 8, 2023. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:53 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-007439 · rdgdoc.xml · nonDerivative · entry 1 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,750 F1 · shares: Grant of shares upon vesting of restricted stock units, which shall fully vest on December 8, 2023. Read SEC document |
| March 28, 2022 Filed Mar 31, 2022 01:24 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 262,500 | $0.00 Strike: $5.09 | $0.00 |
DisclosureSEC source: 0001437749-22-007741 · rdgdoc.xml · derivative · entry 2 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,500 Underlying: Common Stock · 262,500 shares Expires 2032-03-27 F2 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 28, 2023, the first anniversary of the date that the grant was approved by the board of directors, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 28, 2026. Read SEC document |
| March 28, 2022 Filed Mar 31, 2022 01:24 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 43,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-007741 · rdgdoc.xml · nonDerivative · entry 1 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,750 F1 · shares: Grant of shares upon vesting of restricted stock units. Twenty five percent of the shares underlying the award shall vest on each anniversary of the grant date, so that the restricted stock units would be fully vested on the fourth anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.